Get started
Author

Erin Morris

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease
2014 · M Bhatia, Z Jin, et al. · Bone Marrow Transplantation · 108
A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
2003 · Manuela Orjuela, Thomas G Gross, et al. · PubMed · 88
Transplantation-Related Mortality, Graft Failure, and Survival after Reduced-Toxicity Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation in 100 Consecutive Pediatric Recipients
2012 · Prakash Satwani, Zhezhen Jin, et al. · Transplantation and Cellular Therapy · 80
PDF
Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases
2007 · M B Bradley, P Satwani, et al. · Bone Marrow Transplantation · 71
An Age-Dependent Pharmacokinetic Study of Intravenous and Oral Mycophenolate Mofetil in Combination with Tacrolimus for GVHD Prophylaxis in Pediatric Allogeneic Stem Cell Transplantation Recipients
2009 · Monica Bhatia, Olga Militano, et al. · Transplantation and Cellular Therapy · 56
Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord Blood Transplantation in Children with Sickle Cell Disease
2013 · Kavita Radhakrishnan, Monica Bhatia, et al. · Transplantation and Cellular Therapy · 47
PDF
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future Challenges
2005 · Prakash Satwani, Lauren Harrison, et al. · Transplantation and Cellular Therapy · 38
Minimal disease assessment in the treatment of children and adolescents with intermediate‐risk (Stage III/IV) B‐cell non‐Hodgkin lymphoma: a children’s oncology group report
2011 · Bruce Shiramizu, Stanton Goldman, et al. · British Journal of Haematology · 36
T cell depletion utilizing CD 34+ stem cell selection and CD 3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients
2012 · Mark B. Geyer, Angela M. Ricci, et al. · British Journal of Haematology · 35
PDF
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents
2010 · J Styczynski, B Tallamy, et al. · Bone Marrow Transplantation · 35
Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality
2011 · Diane George, Nader Kim El‐Mallawany, et al. · British Journal of Haematology · 29
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning†
2008 · Ian M. Waxman, Olga Militano, et al. · Pediatric Transplantation · 20
Assessment of Minimal Residual Disease in Childhood Non-Hodgkin Lymphoma by Polymerase Chain Reaction Using Patient-Specific Primers
2003 · Vani Sabesan, Mitchell S. Cairo, et al. · Journal of Pediatric Hematology/Oncology · 19
Safety and Efficacy of Myeloablative Conditioning Autologous Stem Cell Transplantation, Targeted Immunotherapy, and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Children, Adolescents, and Young Adults with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
2019 · Aliza Gardenswartz, Brinda Mehta, et al. · Transplantation and Cellular Therapy · 7
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease
2022 · Yaya Chu, Julie-An Talano, et al. · Frontiers in Immunology · 6
PDF
Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma
2016 · J Hochberg, L Harrison, et al. · Bone Marrow Transplantation · 5
Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma
2019 · Anthony N. Audino, Matthew J. Barth, et al. · Blood · 4
Defibrotide Reduces Hypercoagulable State in Patients with Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)
2024 · Edo Schaefer, Morgan Anderson-Crannage, et al. · Blood · 3
PDF
Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)
2020 · Allyson M. Flower, Rachel Friedmann, et al. · Blood · 3
Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)
2017 · Julie-An M. Talano, Cori Abikoff, et al. · Transplantation and Cellular Therapy · 3
PDF
3: Reduced Intensity (RI) aLlogeneic Cord Blood Hematopoietic Cell Transplantation (Allo-CBHCT) in Pediatric Patients with Malignant and Non-Malignant Diseases
2006 · P. Satwani, G. Del Toro, et al. · Transplantation and Cellular Therapy · 3
PDF
Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)
2018 · Mitchell Cairo, Susan K Parsons, et al. · Blood · 2
A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)
2016 · Michelle Nash, Lauren Harrison, et al. · Transplantation and Cellular Therapy · 2
A Phase II Study to Evaluate the Safety and Efficacy of Defibrotide and Changes in Plasma Biomarkers in Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)
2023 · Edo Schaefer, Morgan Anderson-Crannage, et al. · Blood · 1
PDF
A Phase II Study to Evaluate the Safety and Efficacy of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)
2022 · Edo Schaefer, Temima Kanarfogel, et al. · Blood · 1
Works count: 56
Citation count: 711
H-index: 13
I10-index: 13
Year
Topic
Type